On the 20th, Yuhan Corporation announced that it has signed a contract with multinational pharmaceutical company Gilead Sciences to supply the active pharmaceutical ingredient (API) for HIV treatments. The contract is valued at approximately USD 60.7 million (KRW 84.27 billion), representing 4.08% of Yuhan’s total sales last year, and covers the period from March 31, 2026, to February 26, 2027.
Yuhan has been supplying HIV drug APIs to Gilead on an ongoing basis. As the contract exceeds 2.5% of the company’s annual revenue, disclosure is required. Yuhan previously signed similar agreements with Gilead in September 2024 and May 2025, valued at KRW 107.6 billion and KRW 88.8 billion, respectively.
To learn more, please click here:
#Yuhan, #YuhanUSA, #Gilead Sciences, #HIV, #API